Evaluation of the adjuvant activity of naloxone, an opioid receptor antagonist, in combination with heat-killed Listeria monocytogenes vaccine

Microbes and Infection

Volumn 12, Issue 5, 2010, Pages 382-388

  Jazani, Nima Hosseini ^a   Karimzad, Mojtaba ^a   Mazloomi, Ebrahim ^b   Sohrabpour, Mohammad ^b   Hassan, Zuhair Muhammad ^c   Ghasemnejad, Hojjat ^d   Roshan Milani, Shiva ^a   Shahabi, Shahram ^a  

^a URMIA UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISLAMIC AZAD UNIVERSITY   (Iran)

^c TARBIAT MODARES UNIVERSITY   (Iran)

^d ISLAMIC AZAD UNIVERSITY   (Iran)

Author keywords

Adjuvant; Intracellular bacteria; Naloxone; Opioid; Vaccine

Indexed keywords

BACTERIAL VACCINE; HEAT KILLED LISTERIA MONOCYTOGENES VACCINE; NALOXONE; PHOSPHATE BUFFERED SALINE; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BAGG ALBINO MOUSE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; HYPERSENSITIVITY; IMMUNIZATION; LISTERIA MONOCYTOGENES; LISTERIOSIS; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TH1 CELL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; BACTERIAL VACCINES; CELL PROLIFERATION; HUMANS; HYPERSENSITIVITY, DELAYED; LISTERIA INFECTIONS; LISTERIA MONOCYTOGENES; LYMPHOCYTES; MALE; MICE; MICE, INBRED BALB C; NALOXONE; SURVIVAL ANALYSIS; TH1 CELLS; VACCINES, INACTIVATED;

HUMAN HERPESVIRUS 1; LISTERIA MONOCYTOGENES; MUS;

EID: 77950859901     PISSN: 12864579     EISSN: 1769714X     Source Type: Journal    
DOI: 10.1016/j.micinf.2010.02.001     Document Type: Article

References (36)

1. Romagnani S. Regulation of the T cell response. Clin. Exp. Allergy 36 (2006) 1357-1366
2. Claassen E., de Leeuw W., de Greeve P., Hendriksen C., and Boersma W. Freund's complete adjuvant: an effective but disagreeable formula. Res. Immunol. 143 (1992) 478-483
3. Tagliabue A., and Rappuoli R. Vaccine adjuvants: the dream becomes real. Hum Vaccine 4 (2008) 347-349
4. Perrie Y., Mohammed A.R., Kirby D.J., McNeil S.E., and Bramwell V.W. Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens. Int. J. Pharm. 364 (2008) 272-280
5. Lewcock A. http://www.in-pharmatechnologist.com/Materials-Formulation/New-pandemic-flu-vaccine-gets-EU-approval
6. Heinemann L., Woodfield L., Amer M., and Hibma M. Effective induction of type 1 helper IgG2a and cytotoxic T-cell responses in mice following immunization with human papillomavirus type 16 E2 in MF59. Viral Immunol. 21 (2008) 225-233
7. Mbawuike I.N., Acuna C., Caballero D., Pham-Nguyen K., Gilbert B., Petribon P., and Harmon M. Reversal of age-related deficient influenza virus-specific CTL responses and IFN-gamma production by monophosphoryl lipid A. Cell Immunol 173 (1996) 64-78
8. Hem S.L., and White J.L. Structure and properties of aluminum-containing adjuvants. Pharm. Biotechnol. 6 (1995) 249-276
9. McCarthy L., Wetzel M., Sliker J.K., Eisenstein T.K., and Rogers T.J. Opioids, opioid receptors, and the immune response. Drug Alcohol Depend 62 (2001) 111-123
10. Sharp B.M. Multiple opioid receptors on immune cells modulate intracellular signaling. Brain Behav Immun 20 (2006) 9-14
11. Molitor T.W., Morilla A., Risdahl J.M., Murtaugh M.P., Chao C.C., and Peterson P.K. Chronic morphine administration impairs cell-mediated immune responses in swine. J. Pharmacol. Exp. Ther. 260 (1992) 581-586
12. Carpenter G.W., and Carr D.J. Pretreatment with beta-funaltrexamine blocks morphine-mediated suppression of CTL activity in alloimmunized mice. Immunopharmacology 29 (1995) 129-140
13. Friedman H., Newton C., and Klein T.W. Microbial infections, immunomodulation, and drugs of abuse. Clin. Microbiol. Rev. 16 (2003) 209-219
14. Sacerdote P., Gaspani L., and Panerai A.E. The opioid antagonist naloxone induces a shift from type 2 to type 1 cytokine pattern in normal and skin-grafted mice. Ann. N. Y Acad. Sci. 917 (2000) 755-763
15. Sacerdote P., di San Secondo V.E., Sirchia G., Manfredi B., and Panerai A.E. Endogenous opioids modulate allograft rejection time in mice: possible relation with Th1/Th2 cytokines. Clin Exp Immunol 113 (1998) 465-469
16. Sacerdote P., Manfredi B., Gaspani L., and Panerai A.E. The opioid antagonist naloxone induces a shift from type 2 to type 1 cytokine pattern in BALB/cJ mice. Blood 95 (2000) 2031-2036
17. (2008). http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm
18. Burris S., Norland J., and Edlin B.R. Legal aspects of providing naloxone to heroin users in the United States. Int J Drug Pol 12 (2001) 237-248
19. Jamali A., Mahdavi M., Shahabi S., Hassan Z.M., Sabahi F., Javan M., Farsani M.J., Parsania M., and Bamdad T. Naloxone, an opioid receptor antagonist, enhances induction of protective immunity against HSV-1 infection in BALB/c mice. Microb. Pathog. 43 (2007) 217-223
20. Jamali A., Mahdavi M., Hassan Z.M., Sabahi F., Farsani M.J., Bamdad T., Soleimanjahi H., Motazakker M., and Shahabi S. A novel adjuvant, the general opioid antagonist naloxone, elicits a robust cellular immune response for a DNA vaccine. Int. Immunol. 21 (2009) 217-225
21. Yeung V.P., Gieni R.S., Umetsu D.T., and DeKruyff R.H. Heat-killed Listeria monocytogenes as an adjuvant converts established murine Th2-dominated immune responses into Th1-dominated responses. J. Immunol. 161 (1998) 4146-4152
22. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65 (1983) 55-63
23. Coligan J.E., Strober W., and Margulies D.H. Short protocols in immunology: a compendium of methods from current protocols. Immunology (2005), John Wiley & Sons, Hoboken
24. Barcellini W., Sacerdote P., Borghi M.O., Rizzardi G.P., Fain C., De Giuli Morghen C., Manfredi B., Lazzarin A., Meroni P.L., and Panerai A.E. Beta-endorphin content in HIV-infected HuT78 cell line and in peripheral lymphocytes from HIV-positive subjects. Peptides 15 (1994) 769-775
25. In: Poole V., and Peterson A.M. (Eds). Pharmacotherapeutics for Advanced Practice: A Practical Approach (2005), Lippincott Williams & Wilkins, Philadelphia
26. Philippe D., Dubuquoy L., Groux H., Brun V., Chuoi-Mariot M.T., Gaveriaux-Ruff C., Colombel J.F., Kieffer B.L., and Desreumaux P. Anti-inflammatory properties of the mu opioid receptor support its use in the treatment of colon inflammation. J. Clin. Invest. 111 (2003) 1329-1338
27. Khalil Z., and Helme R.D. Modulation of a peripheral inflammatory response to substance P by locally administered opioid receptor agonists. Neuropeptides 17 (1990) 45-53
28. Sternberg E.M. Neural regulation of innate immunity: a coordinated nonspecific host response to pathogens. Nat Rev Immunol 6 (2006) 318-328
29. Chakass D., Philippe D., Erdual E., Dharancy S., Malapel M., Dubuquoy C., Thuru X., Gay J., Gaveriaux-Ruff C., Dubus P., Mathurin P., Kieffer B.L., Desreumaux P., and Chamaillard M. Micro-Opioid receptor activation prevents acute hepatic inflammation and cell death. Gut 56 (2007) 974-981
30. Kirst A., Wack C., Lutz W.K., Eggert A., Kampgen E., and Fischer W.H. Expression of functional kappa-opioid receptors on murine dendritic cells. Immunol. Lett. 84 (2002) 41-48
31. Sacerdote P. Effects of in vitro and in vivo opioids on the production of IL-12 and IL-10 by murine macrophages. Ann. N. Y Acad. Sci. 992 (2003) 129-140
32. Mathers A.R., Tckacheva O.A., Janelsins B.M., Shufesky W.J., Morelli A.E., and Larregina A.T. In vivo signaling through the neurokinin 1 receptor favors transgene expression by langerhans cells and promotes the generation of Th1- and Tc1-biased immune responses. J Immunol 178 (2007) 7006-7017
33. Berman A.S., Chancellor-Freeland C., Zhu G., and Black P.H. Substance P primes murine peritoneal macrophages for an augmented proinflammatory cytokine response to lipopolysaccharide. Neuroimmunomodulation 3 (1996) 141-149
34. Bileviciute-Ljungar I., and Spetea M. Contralateral but not systemic administration of the kappa-opioid agonist U-50,488H induces anti-nociception in acute hindpaw inflammation in rats. Br. J. Pharmacol. 132 (2001) 252-258
35. Kaneider N.C., Kaser A., Dunzendorfer S., Tilg H., Patsch J.R., and Wiedermann C.J. Neurokinin-1 receptor interacts with PrP(106-126)-induced dendritic cell migration and maturation. J. Neuroimmunol. 158 (2005) 153-158
36. Pamer E.G. Immune responses to Listeria monocytogenes. Nat. Rev. Immunol. 4 (2004) 812-823